CARL

Carlsmed

Positive
Neutral
Negative
Sentiment 3-Months
Positive
Neutral 66.7%
Negative

Positive
Zacks Investment Research
8 days ago
Wall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This High?
The consensus price target hints at a 51.9% upside potential for Carlsmed, Inc. (CARL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 51.94% Upside in Carlsmed, Inc. (CARL): Can the Stock Really Move This High?
Neutral
Seeking Alpha
20 days ago
Carlsmed, Inc. (CARL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Carlsmed, Inc. (CARL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Carlsmed, Inc. (CARL) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Positive
Zacks Investment Research
25 days ago
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet
The mean of analysts' price targets for Carlsmed, Inc. (CARL) points to a 90.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Carlsmed, Inc. (CARL) Could Surge 90.77%: Read This Before Placing a Bet
Neutral
Seeking Alpha
27 days ago
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript
Carlsmed, Inc. (CARL) Q1 2026 Earnings Call Transcript
Negative
Zacks Investment Research
27 days ago
Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates
Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to a loss of $1.47 per share a year ago.
Carlsmed, Inc. (CARL) Reports Q1 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
28 days ago
Carlsmed® Reports First Quarter 2026 Financial Results
First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today reported financial results for the first quarter ended March 31, 2026.
Carlsmed® Reports First Quarter 2026 Financial Results
Neutral
GlobeNewsWire
1 month ago
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences.
Carlsmed, Inc. To Participate in Upcoming Investor Conferences
Neutral
GlobeNewsWire
1 month ago
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.
Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026
Neutral
GlobeNewsWire
2 months ago
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET.
Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference
Neutral
Seeking Alpha
3 months ago
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript
Carlsmed, Inc. (CARL) Q4 2025 Earnings Call Transcript